Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000998567 | SCV001154697 | likely benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | TNXB: BP4, BP7 |
Gene |
RCV000998567 | SCV001781897 | likely benign | not provided | 2021-03-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002327226 | SCV002630690 | likely benign | Cardiovascular phenotype | 2019-06-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002505523 | SCV002813622 | likely benign | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2022-01-03 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000998567 | SCV005225633 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Genome Diagnostics Laboratory, |
RCV000998567 | SCV001806874 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000998567 | SCV001927816 | likely benign | not provided | no assertion criteria provided | clinical testing |